Vanguard Group Inc. Has $19.86 Million Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Vanguard Group Inc. grew its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 2.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,813,759 shares of the company’s stock after purchasing an additional 40,407 shares during the period. Vanguard Group Inc. owned about 0.05% of iTeos Therapeutics worth $19,861,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of iTeos Therapeutics by 4.9% in the 2nd quarter. BlackRock Inc. now owns 4,680,194 shares of the company’s stock valued at $61,966,000 after purchasing an additional 216,888 shares in the last quarter. State Street Corp boosted its stake in shares of iTeos Therapeutics by 44.8% in the 2nd quarter. State Street Corp now owns 2,478,332 shares of the company’s stock valued at $51,054,000 after purchasing an additional 766,441 shares in the last quarter. Morgan Stanley boosted its stake in shares of iTeos Therapeutics by 1.6% in the 4th quarter. Morgan Stanley now owns 846,859 shares of the company’s stock valued at $16,539,000 after purchasing an additional 12,965 shares in the last quarter. 683 Capital Management LLC boosted its stake in shares of iTeos Therapeutics by 38.5% in the 3rd quarter. 683 Capital Management LLC now owns 810,000 shares of the company’s stock valued at $8,870,000 after purchasing an additional 225,000 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new stake in shares of iTeos Therapeutics in the 3rd quarter valued at approximately $7,917,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on ITOS. HC Wainwright reiterated a “buy” rating and issued a $44.00 price objective on shares of iTeos Therapeutics in a report on Thursday, March 7th. Wedbush reiterated an “outperform” rating and issued a $18.00 price objective (down previously from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th.

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock opened at $11.72 on Monday. iTeos Therapeutics, Inc. has a 52-week low of $8.20 and a 52-week high of $18.24. The firm has a 50 day moving average price of $11.35 and a two-hundred day moving average price of $10.58. The firm has a market cap of $420.04 million, a price-to-earnings ratio of -3.72 and a beta of 1.19.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.18. As a group, equities research analysts predict that iTeos Therapeutics, Inc. will post -4.76 EPS for the current fiscal year.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.